NCT01232543View on ClinicalTrials.gov

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

November 30, 2011

Conditions
Atopic Dermatitis
Interventions
DRUG

Product 0405

Product 0405 will be administered topically, twice daily for 28 days.

Trial Locations (1)

11747

Fougera Pharmaceuticals Inc., Melville

Sponsors
All Listed Sponsors
lead

Fougera Pharmaceuticals Inc.

INDUSTRY